Is there any role left for p210-derived peptide vaccines in chronic myeloid leukemia?

Despite the fact that the idea of educating the immune system against tumor-specific antigens by using an active immunotherapy such as a vaccine has been pursued by many researchers, consistent clinical data on the effectiveness of anticancer vaccines have not yet been produced. Lack of tumor specific targets, low immunogenicity of the tumorassociated antigens, inappropriate vaccine formulation and large tumor burdens of the vaccinated patients are some of the most frequent reasons accounting for the current disappointing results with anticancer vaccines.